Climb Bio, Inc. (CLYM)
- Previous Close
1.2000 - Open
1.2100 - Bid 1.1500 x 100
- Ask 1.2600 x 100
- Day's Range
1.1700 - 1.2100 - 52 Week Range
1.0500 - 10.2300 - Volume
121,424 - Avg. Volume
240,326 - Market Cap (intraday)
81.767M - Beta (5Y Monthly) -0.11
- PE Ratio (TTM)
-- - EPS (TTM)
-1.5300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.00
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN). The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
climbbio.comRecent News: CLYM
View MorePerformance Overview: CLYM
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLYM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLYM
View MoreValuation Measures
Market Cap
81.77M
Enterprise Value
-68.62M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.39
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-10.30%
Return on Equity (ttm)
-46.26%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-73.9M
Diluted EPS (ttm)
-1.5300
Balance Sheet and Cash Flow
Total Cash (mrq)
150.92M
Total Debt/Equity (mrq)
0.25%
Levered Free Cash Flow (ttm)
-9.54M